The Latest Cardiac and Vascular News
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS ® (mavacamten) PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific […]
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association’s Scientific Sessions, November 16-18, 2024 in Chicago, IL.
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
November 07, 2024 08:00 AM Eastern Standard Time BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. “Based on the strength of clinical and preclinical data to-date, we are treating patients with […]
DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing […]
VA physicians can now access the solutions through Federal Supply Schedule and Defense Logistics Agency ECAT Contract System MOUNTAIN VIEW, Calif., Nov. 7, 2024 /PRNewswire/ — AliveCor, the global leader in AI-powered cardiology, today announced the activation of its services and…
MIAMI, Nov. 7, 2024 /PRNewswire/ — Pedro Martinez-Clark, MD, FACC, a renowned Harvard-trained cardiologist and founder of Amavita Heart and Vascular™, has joined forces with LimFlow® to offer an innovative solution for patients suffering from chronic limb-threatening ischemia (CLTI)….
The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy1 Approval is supported by the admIRE study, where 85% peak primary…
LOS ANGELES, Nov. 07, 2024 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that ONRAD, Inc. (“ONRAD”), a national full-service radiology provider has selected RadNet’s DeepHealth OS to advance its next generation of radiology services. By utilizing the cloud-native and modular capabilities of DeepHealth OS, ONRAD will implement a customized solutions roadmap targeted to streamline its clinical and operational workflows, enhancing productivity, and ultimately improving patient outcomes through AI-powered, unified data integration.
